Tradestie Institutional Equity Comparison Engine
PLYX vs SER โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
SER Overall Edge
SER Captures Institutional Edge (2โ0 Pillars ยท 6โ1 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Serina Therapeutics, Inc. (SER) driven by superior Growth & Margin, Momentum & Technical. Fundamentally, PLYX trades at N/M Forward P/E with N/A operating margin (N/A YoY revenue) versus SER at N/M Forward P/E and 0.0% operating margin (+154.9% YoY). In options structure, PLYX sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against SER sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
PLYX N/M vs SER N/M Fwd P/E
Growth & Margin Winner
SER
Op Margin N/A vs 0.0% ยท YoY N/A vs +154.9%
Momentum & Technical Winner
SER
1Y -95.7% vs -68.1% ยท 52W Pos 0% vs 2%
Options & Structure Winner
Tie
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (N/A IV)
PLYX
US Equity
PLYX
Institutional Equity
$1.51
-6.21% 1D
Market Cap
N/A
1M Return
-22.16%
1Y Return
-95.69%
Forward P/E
N/M
Unified AI Score
43.3 / 100
HOLD
Tech 33.0
Fund 52.0
Flow 50.0
Mom 60.0
SER
NYSE American
Serina Therapeutics, Inc.
Pharmaceutical Preparations
$1.20
-11.11% 1D
Market Cap
$35.9M
1M Return
-32.2%
1Y Return
-68.09%
Forward P/E
N/M
Unified AI Score
43.1 / 100
HOLD
Tech 25.0
Fund 57.0
Flow 50.0
Mom 59.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
PLYX -95.69%
SER -68.09%
Spread: +39.81 pp (SER Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
PLYX TTM Op. Margin: N/A
SER TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on PLYX vs SER. Trailing 12-month operating profitability (PLYX N/A vs SER 0.0%) and valuation multiples (PLYX N/M vs SER N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | PLYX | SER | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | N/A | $35.9M | Larger Scale | SER |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | N/A | +154.9% | Higher Growth | SER |
| Operating Margin (TTM) Profitability | N/A | 0.0% | Higher Margin | SER |
| Net Profit Margin Profitability | N/A | 0.0% | Higher Margin | SER |
| Return on Equity (ROE) Capital Efficiency | N/A | -207.9% | Higher ROE | SER |
| 52-Week Range Position Momentum | 0% ($2โ$49) | 2% ($1โ$4) | Stronger Trend | SER |
| Beta / 30D Volatility Risk Regime | 1.43ฮฒ ยท 60% Vol | 1.40ฮฒ ยท 98% Vol | Lower Realized Risk | PLYX |
| Unified Institutional Score Composite Signal | 43.3 / 100 (HOLD) | 43.1 / 100 (HOLD) | Higher Composite | Tie |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full PLYX vs SER Buy Guide
PLYX
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
SER
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither PLYX nor SER registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.